Sunho Biologics, Inc
Sunho Biologics, Inc. is a biopharmaceutical company specializing in the development and commercialization of immunotherapies, including immunocytokines, to treat cancers and autoimmune diseases. Their innovative products aim to provide affordable medicine and overcome current treatment limitations for patients worldwide.
Sharlife Shariah Status :
No
| Allocation | Shares | % |
|---|---|---|
| Hong Kong Offer | ||
| International Offer |
Income Statement
| - | 31/12/2022 | 31/12/2023 | % Growth | |
|---|---|---|---|---|
| Revenue | ||||
| Other Income | ||||
| Interest Income | ||||
| Profit After Tax | ||||
| PAT Margin % |
Balance Sheet
| - | 31/12/2022 | 31/12/2023 | % Growth | |
|---|---|---|---|---|
| Non-current Assets | ||||
| Current Assets | ||||
| Non Current Liabilities | ||||
| Current Liabilities | ||||
| Deferred Liabilities | ||||
| Total Assets | ||||
| Total Liabilities |
Capital & Reserves
| - | 31/12/2022 | 31/12/2023 | % Growth | |
|---|---|---|---|---|
| Share Capital | ||||
| Retained Earnings | ||||
| Reserves | ||||
| Working Capital | ||||
| Shareholder Fund |
Ratio
0 = Lowest | 5 = Highest
| - | - | 31/12/2022 | Score | 31/12/2023 | Score | % Growth | |
|---|---|---|---|---|---|---|---|
| Current Ratio (Liquidity) | |||||||
| Debt Ratio (Leverage) | |||||||
| Gearing Ratio (Leverage) | |||||||
| Return on Capital Employed | |||||||
| Total Assets Turnover |
Altman-Z
| - | 31/12/2022 | 31/12/2023 | Overall weighted score |
|---|---|---|---|
| Company P/E ratio | |
|---|---|
| Peers | P/E |
| Checklist | Remarks |
|---|---|
| Revenue |